Theriva Biologics, Inc. (TOVX) Investor Relations Documents

Theriva Biologics, Inc. (TOVX) investor relations documents from the company's IR site: 1 presentation, 21 press releases; latest deck 2026-05-13. Read in-app with summaries. First-party data.

Corporate Presentation (PDF): Theriva Biologics is developing VCN-01, a stroma-degrading oncolytic virus, with a lead Phase 3 program for metastatic pancreatic cancer.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-11Press releaseTheriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
2026-08-11Press releaseTheriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de
2026-08-06Press releaseTheriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of
2026-08-06Press releaseTheriva™ Biologics anuncia que se ha administrado la primera dosis a un paciente en el ensayo clínico VIRAGE2 de Fase II
2026-07-07Press releaseTheriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More
2026-07-07Press releaseTheriva™ Biologics anuncia que ha obtenido la autorización reglamentaria para llevar a cabo el ensayo clínico de Fase II
2026-06-11Press releaseTheriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Ca
2026-06-11Press releaseTheriva™ Biologics anuncia los resultados del ensayo clínico de Fase I con VCN-01 para el cáncer de cabeza y cuello, pub
2026-05-13PresentationCorporate Presentation (PDF)
2026-05-07Press releaseTheriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de
2026-05-05Press releaseTheriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
2026-04-18Press releaseTheriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01
2026-04-17Press releaseTheriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01
2026-04-17Press releaseTheriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01
2026-03-23Press releaseTheriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VC
2026-03-23Press releaseTheriva™ Biologics anuncia el resultado positivo de la reunión de cierre de la fase 2 con la FDA de EE. UU. sobre el dis
2026-03-13Press releaseTheriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del ejercicio 2025
2026-03-12Press releaseTheriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
2026-02-18Press releaseTheriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
2026-02-18Press releaseTheriva™ Biologics concede la licencia de SYN-020 a Rasayana Therapeutics para numerosas indicaciones
2026-02-03Press releaseTheriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 202
2026-02-03Press releaseTheriva™ Biologics anuncia la próxima presentación de los datos del ensayo clínico de Fase 1 del VCN-01 para el retinobl

TOVX overview · TOVX earnings · TOVX financials · TOVX KPIs · TOVX ownership · TOVX peers · TOVX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.